Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV
Trinity Biotech Receives Early Approval From The WHO To Begin Offshore Manufacturing Of TrinScreen HIV & Uni-Gold HIV
Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced an important update on its Comprehensive Transformation Plan, which includes the transfer of manufacturing of both TrinScreen HIV and Uni-Gold HIV to a lower-cost offshore manufacturing partner. Trinity Biotech has received earlier than expected approval from the World Health Organization (WHO) to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at its outsourced provider. This approval was a key prerequisite in the manufacturing transfer the Company has been working towards as part of its Comprehensive Transformation Plan.
Trinity Biotech plc (納斯達克:TRIB)是一家專注於人類診斷和糖尿病管理解決方案的商業階段生物技術公司，包括可穿戴生物傳感器，今天宣佈了其綜合轉型計劃的重要更新，該計劃包括將TrinScreen HIV和Uni-Gold HIV的製造轉移到一個更低成本的海外製造合作伙伴。Trinity Biotech已提前獲得世界衛生組織（WHO）的批准，允許在其外包提供商處進行TrinScreen HIV和Uni-Gold HIV的後期製造過程。該批准是公司爲了實施綜合轉型計劃而進行製造轉移的重要前提。
譯文內容由第三人軟體翻譯。
